Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 17.871
Filtrer
1.
AAPS J ; 26(4): 81, 2024 Jul 12.
Article de Anglais | MEDLINE | ID: mdl-38992298

RÉSUMÉ

Lack of Factor VIII (FVIII) concentrates is one of limiting factors for Hemophilia A prophylaxis in resource-limited countries. Rondaptivon pegol (BT200) is a pegylated aptamer and has been shown to elevate the level of von Willebrand Factor (VWF) and FVIII in previous studies. A population pharmacokinetic model for BT200 was built and linked to the kinetic models of VWF and FVIII based on reasonable assumptions. The developed PK/PD model for BT200 described the observed kinetic of BT200, VWF, and FVIII in healthy volunteers and patients with mild-to-moderate hemophilia A from two clinical trials. The developed model was evaluated using an external dataset in patients with severe hemophilia A taking recombinant FVIII products. The developed and evaluated PK/PD model was able to describe and predict concentration-time profiles of BT200, VWF, and FVIII in healthy volunteers and patients with hemophilia A. Concentration-time profiles of FVIII were then predicted following coadministration of plasma-derived FVIII concentrate and BT200 under various dosing scenarios in virtual patients with severe hemophilia A. Plasma-derived products, that contain VWF, are more accessible in low-resource countries as compared to their recombinant counterparts. The predicted time above 1 and 3 IU/dL FVIII in one week was compared between scenarios in the absence and presence of BT200. A combination dose of 6 mg BT200 once weekly plus 10 IU/kg plasma-derived FVIII twice weekly maintained similar coverage to a 30 IU/kg FVIII thrice weekly dose in absence of BT200, representing only 22% of the FVIII dose per week.


Sujet(s)
Facteur VIII , Hémophilie A , Facteur de von Willebrand , Humains , Facteur VIII/pharmacocinétique , Facteur VIII/administration et posologie , Hémophilie A/traitement médicamenteux , Hémophilie A/sang , Facteur de von Willebrand/pharmacocinétique , Facteur de von Willebrand/administration et posologie , Modèles biologiques , Adulte , Mâle , Jeune adulte , Cinétique , Polyéthylène glycols/pharmacocinétique , Polyéthylène glycols/administration et posologie , Adolescent
2.
Trials ; 25(1): 432, 2024 Jul 02.
Article de Anglais | MEDLINE | ID: mdl-38956697

RÉSUMÉ

BACKGROUND: Norepinephrine and phenylephrine are commonly used vasoactive drugs to treat hypotension during the perioperative period. The increased release of endogenous norepinephrine elicits prothrombotic changes, while parturients are generally in a hypercoagulable state. Therefore, this trial aims to investigate whether there is a disparity between equivalent doses of prophylactic norepinephrine infusion and phenylephrine infusion on prothrombotic response in patients undergoing cesarean section under spinal anesthesia. METHODS: Sixty-six eligible parturients will be recruited for this trial and randomly assigned to the norepinephrine or phenylephrine group. The "study drug" will be administered at a rate of 15 ml/h starting from the intrathecal injection. The primary outcome are plasma coagulation factor VIII activity (FVIII: C), fibrinogen, and D-dimer levels. The secondary outcomes include hemodynamic variables and umbilical artery blood pH value. DISCUSSION: Our study is the first trial comparing the effect of norepinephrine and phenylephrine on prothrombotic response in patients undergoing cesarean section under spinal anesthesia. Positive or negative results will all help us better understand the impact of vasoactive drugs on patients. If there are any differences, this trial will provide new evidence for maternal choice of vasoactive medications in the perioperative period. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2300077164. Registered on 1 November 2023. https://www.chictr.org.cn/ .


Sujet(s)
Anesthésie obstétricale , Rachianesthésie , Césarienne , Norépinéphrine , Phényléphrine , Essais contrôlés randomisés comme sujet , Vasoconstricteurs , Humains , Césarienne/effets indésirables , Rachianesthésie/effets indésirables , Femelle , Norépinéphrine/sang , Méthode en double aveugle , Grossesse , Phényléphrine/administration et posologie , Vasoconstricteurs/usage thérapeutique , Anesthésie obstétricale/effets indésirables , Anesthésie obstétricale/méthodes , Adulte , Produits de dégradation de la fibrine et du fibrinogène/métabolisme , Produits de dégradation de la fibrine et du fibrinogène/analyse , Facteur VIII , Résultat thérapeutique , Coagulation sanguine/effets des médicaments et des substances chimiques , Hémodynamique/effets des médicaments et des substances chimiques
4.
N Engl J Med ; 391(3): 235-246, 2024 Jul 18.
Article de Anglais | MEDLINE | ID: mdl-39018533

RÉSUMÉ

BACKGROUND: Once-weekly efanesoctocog alfa provides high sustained factor VIII activity with superior bleeding prevention as compared with prestudy factor VIII prophylaxis in previously treated patients 12 years of age or older with severe hemophilia A. Data on outcomes of efanesoctocog alfa treatment in children younger than 12 years of age with severe hemophilia A are limited. METHODS: We conducted a phase 3, open-label study involving previously treated patients younger than 12 years of age with severe hemophilia A. Patients received prophylaxis with once-weekly efanesoctocog alfa (50 IU per kilogram of body weight) for 52 weeks. The primary end point was the occurrence of factor VIII inhibitors (neutralizing antibodies against factor VIII). Secondary end points included annualized rates of treated bleeding episodes, bleeding treatment, safety, and pharmacokinetics. RESULTS: A total of 74 male patients were enrolled (38 with an age of <6 years and 36 with an age of 6 to <12 years). No factor VIII inhibitors developed. Most adverse events were nonserious. No serious adverse events that were assessed by the investigator as being related to efanesoctocog alfa were reported. In the 73 patients treated according to the protocol, the median and model-based mean annualized bleeding rates were 0.00 (interquartile range, 0.00 to 1.02) and 0.61 (95% confidence interval, 0.42 to 0.90), respectively. A total of 47 patients (64%) had no treated bleeding episodes, 65 (88%) had no spontaneous bleeding episodes, and 61 (82%) had no episodes of bleeding into joints. A total of 41 of 43 bleeding episodes (95%) resolved with one injection of efanesoctocog alfa. Mean factor VIII activity at steady state was more than 40 IU per deciliter for 3 days and more than 10 IU per deciliter for almost 7 days after dose administration. The geometric mean terminal half-life was 40.0 hours. CONCLUSIONS: In children with severe hemophilia A, once-weekly prophylaxis with efanesoctocog alfa provided high sustained factor VIII activity in the normal to near-normal range (>40 IU per deciliter) for 3 days and more than 10 IU per deciliter for almost 7 days after administration, leading to effective bleeding prevention. Efanesoctocog alfa was associated with mainly nonserious adverse events. (Funded by Sanofi and Sobi; XTEND-Kids ClinicalTrials.gov number, NCT04759131.).


Sujet(s)
Facteur VIII , Hémophilie A , Hémorragie , Humains , Hémophilie A/traitement médicamenteux , Hémophilie A/complications , Facteur VIII/immunologie , Facteur VIII/effets indésirables , Facteur VIII/administration et posologie , Facteur VIII/usage thérapeutique , Mâle , Enfant , Enfant d'âge préscolaire , Hémorragie/induit chimiquement , Nourrisson , Anticorps neutralisants/sang , Calendrier d'administration des médicaments
5.
Rinsho Ketsueki ; 65(6): 560-566, 2024.
Article de Japonais | MEDLINE | ID: mdl-38960657

RÉSUMÉ

Acquired hemophilia A (AHA) is a bleeding disorder caused by autoantibody (inhibitor) production targeting blood coagulation factor VIII (FVIII). It is characterized by sudden onset, and often causes extensive and severe bleeding in soft tissue. Acquired hemophilia A is diagnosed when coagulation tests show normal PT, prolonged APTT, decreased FVIII activity, normal VWF activity, and positive FVIII inhibitor. Hemostatic therapy mainly consists of bypass therapy, which activates the extrinsic coagulation pathway, bypassing the need for FVIII or factor IX. Emicizumab, a bispecific antibody that substitutes for FVIII function, can be used to prevent bleeding. Immunosuppressive therapy is necessary to suppress or eradicate inhibitors. The majority of patients go into remission with treatment, but some die from bleeding symptoms or infections associated with immunosuppressive therapy.


Sujet(s)
Hémophilie A , Hémophilie A/traitement médicamenteux , Hémophilie A/thérapie , Humains , Facteur VIII , Anticorps bispécifiques/usage thérapeutique , Immunosuppresseurs/usage thérapeutique , Anticorps monoclonaux humanisés
6.
J Med Virol ; 96(7): e29774, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38953434

RÉSUMÉ

Factor VIII and IX clotting factor concentrates manufactured from pooled plasma have been identified as potent sources of virus infection in persons with hemophilia (PWHs) in the 1970s and 1980s. To investigate the range and diversity of viruses over this period, we analysed 24 clotting factor concentrates for several blood-borne viruses. Nucleic acid was extracted from 14 commercially produced clotting factors and 10 from nonremunerated donors, preserved in lyophilized form (expiry dates: 1974-1992). Clotting factors were tested by commercial and in-house quantitative PCRs for blood-borne viruses hepatitis A, B, C and E viruses (HAV, HBV, HCV, HEV), HIV- types 1/2, parvoviruses B19V and PARV4, and human pegiviruses types 1 and 2 (HPgV-1,-2). HCV and HPgV-1 were the most frequently detected viruses (both 14/24 tested) primarily in commercial clotting factors, with frequently extremely high viral loads in the late 1970s-1985 and a diverse range of HCV genotypes. Detection frequencies sharply declined following introduction of virus inactivation. HIV-1, HBV, and HAV were less frequently detected (3/24, 1/24, and 1/24 respectively); none were positive for HEV. Contrastingly, B19V and PARV4 were detected throughout the study period, even after introduction of dry heat treatment, consistent with ongoing documented transmission to PWHs into the early 1990s. While hemophilia treatment is now largely based on recombinant factor VIII/IX in the UK and elsewhere, the comprehensive screen of historical plasma-derived clotting factors reveals extensive exposure of PWHs to blood-borne viruses throughout 1970s-early 1990s, and the epidemiological and manufacturing parameters that influenced clotting factor contamination.


Sujet(s)
Facteurs de la coagulation sanguine , Pathogènes transmissibles par le sang , Humains , Pathogènes transmissibles par le sang/isolement et purification , Infections transmissibles par le sang/épidémiologie , Infections transmissibles par le sang/virologie , Contamination de médicament , Histoire du 20ème siècle , Hémophilie A , Virus/classification , Virus/isolement et purification , Virus/génétique , Réaction de polymérisation en chaîne , Facteur VIII , Facteurs temps
7.
Blood Coagul Fibrinolysis ; 35(5): 238-247, 2024 Jul 01.
Article de Anglais | MEDLINE | ID: mdl-38874909

RÉSUMÉ

The aim of this study is to characterize zebrafish coagulation cofactors fviii and fv mutant fish and assess if they phenocopy classical hemophilia A and factor V deficiency in humans. The embryos from fviii and fv zebrafish heterozygote mutants generated by ENU mutagenesis were purchased from the ZIRC repository. They were reared to adulthood and genotyped. The heterozygote male and female were crossed to get homozygote, heterozygote, and wild-type fish. Functional kinetic coagulation assays and bleeding assays were performed on normal and mutant adult fish, and venous laser injury assays were performed on the larvae. The DNA from fviii and fv mutants were sequenced to confirm if they have a premature stop codon in exon 19, and in exon 2, respectively, and in both mutants, the amino acid glutamine is replaced with a stop codon. Homozygous and heterozygous 5 days post fertilization (dpf) larvae for fviii and fv deficient mutants exhibited prolonged time to occlusion after venous laser injury compared to wild-type controls. The homozygous and heterozygous fviii adult mutants showed modest bleeding and delayed fibrin formation in the kinetic partial thromboplastin time (kPTT) assay with their plasma. fv homozygous larvae had poor survival beyond 12 dpf. However, heterozygous fv mutants exhibited heavy bleeding and prolonged fibrin formation in the kPTT and kPT assay compared with wild-type siblings. Our characterization showed fviii and fv mutants from ZIRC phenocopied to a considerable extent classical hemophilia A and factor V deficiency in humans, respectively. These models should be useful in studying and developing novel drugs that reverse the phenotype and in generating suppressor mutations to identify novel factors that compensate for these deficiencies.


Sujet(s)
Modèles animaux de maladie humaine , Déficit en facteur V , Facteur VIII , Hémophilie A , Danio zébré , Animaux , Hémophilie A/génétique , Hémophilie A/sang , Facteur VIII/génétique , Facteur VIII/métabolisme , Déficit en facteur V/génétique , Proaccélérine/génétique , Mutation , Femelle , Mâle , Coagulation sanguine , Humains
8.
Thromb Res ; 240: 109061, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38870771

RÉSUMÉ

BACKGROUND: Von Willebrand Disease (VWD) is the most common inherited bleeding disorder. VWD is characterized by an abnormal quantity or quality of von Willebrand Factor (VWF). Anemia is often found at presentation for a bleeding disorder evaluation due to chronic blood loss. OBJECTIVES/HYPOTHESIS: We hypothesized that anemia is associated with elevations in both VWF and factor VIII (FVIII) over baseline. We also hypothesized that obesity would be associated with increased levels of VWF. METHODS: We conducted a single-center review of the electronic health record for patients that had proximal von Willebrand profiles and Hb data. RESULTS: We identified 4552 unique subjects with VWF studies and a CBC within 24 h. We found that decreasing hemoglobin inversely correlated with VWF antigen, VWF ristocetin cofactor activity, and FVIII activity. We also found that obesity and Black race were independently associated with increased VWF antigen, activity, and FVIII activity. Hb, race, and body mass index (BMI) continued to be determinants of VWF and FVIII levels in multivariable analysis. CONCLUSION: Our study demonstrates that anemia, race, and BMI were found to be associated with elevation of VWF antigen, VWF activity, and FVIII levels. As many individuals with anemia present for evaluation for a bleeding disorder, these variables need to be considered. KEY POINTS: - Anemia was found to be associated with elevation of VWF antigen, VWF activity and FVIII levels. - Testing von Willebrand factor at times of anemia may mask a diagnosis of von Willebrand Disease.


Sujet(s)
Indice de masse corporelle , Facteur VIII , Hémoglobines , Facteur de von Willebrand , Humains , Facteur de von Willebrand/analyse , Facteur de von Willebrand/métabolisme , Facteur VIII/analyse , Facteur VIII/métabolisme , Mâle , Femelle , Adulte d'âge moyen , Adulte , Hémoglobines/analyse , Maladies de von Willebrand/sang , Anémie/sang , Sujet âgé , Obésité/sang , Obésité/complications
9.
J Orthop Surg Res ; 19(1): 358, 2024 Jun 16.
Article de Anglais | MEDLINE | ID: mdl-38880904

RÉSUMÉ

INTRODUCTION: Haemophilia A (HA) is an X-linked recessive bleeding disorder caused by lack or deficiency of coagulation factor VIII. AIM: The aim of this study is to determine the incidence and treatment-related risk factors of inhibitor development after intensive FVIII replacement for major orthopaedic surgery in previous treated persons with HA. METHODS: A total of 151 HA who underwent 221 major orthopaedic surgical procedures after intensive FVIII treatment were reviewed. The results of inhibitor tests were collected. Potential clinical risk factors for inhibitor development were analyzed. RESULTS: 111 people were diagnosed with severe HA. Thirty-seven persons (24.5%) had history of previous intensive FVIII treatment for surgical procedure. They received a mean perioperative cumulative FVIII of 498 iu/kg within first week after surgery. Seven cases (4.6%) developed an inhibitor post-operatively in our study. Surgical procedure for pseudotumor and the group of persons who experienced postoperative complications had the higher incidence of inhibitor development (9.5%, 13.3% respectively). Only previous history for intensive FVIII exposure was considered as a significant predictor for postoperative inhibitor development after multivariate logistic regression analysis (OR: 29.5, P = 0.002). CONCLUSION: The incidence of inhibitor development in previously treated persons with HA undergoing major orthopaedic surgery was 4.6% and the history of previous intensive FVIII treatment for surgery was associated with higher risk of inhibitor development.


Sujet(s)
Facteur VIII , Hémophilie A , Procédures orthopédiques , Humains , Hémophilie A/traitement médicamenteux , Facteurs de risque , Mâle , Facteur VIII/administration et posologie , Incidence , Adulte , Procédures orthopédiques/effets indésirables , Procédures orthopédiques/méthodes , Adulte d'âge moyen , Adolescent , Jeune adulte , Enfant , Études rétrospectives , Sujet âgé , Femelle , Enfant d'âge préscolaire , Complications postopératoires/épidémiologie , Complications postopératoires/étiologie
10.
J Cell Mol Med ; 28(11): e18460, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38864710

RÉSUMÉ

Haemophilic arthropathy (HA), a common comorbidity in haemophilic patients leads to joint pain, deformity and reduced quality of life. We have recently demonstrated that a long non-coding RNA, Neat1 as a primary regulator of matrix metalloproteinase (MMP) 3 and MMP13 activity, and its induction in the target joint has a deteriorating effect on articular cartilage. In the present study, we administered an Adeno-associated virus (AAV) 5 vector carrying an short hairpin (sh)RNA to Neat1 via intra-articular injection alone or in conjunction with systemic administration of a capsid-modified AAV8 (K31Q) vector carrying F8 gene (F8-BDD-V3) to study its impact on HA. AAV8K31Q-F8 vector administration at low dose, led to an increase in FVIII activity (16%-28%) in treated mice. We further observed a significant knockdown of Neat1 (~40 fold vs. untreated injured joint, p = 0.005) in joint tissue of treated mice and a downregulation of chondrodegenerative enzymes, MMP3, MMP13 and the inflammatory mediator- cPLA2, in mice receiving combination therapy. These data demonstrate that AAV mediated Neat1 knockdown in combination with F8 gene augmentation can potentially impact mediators of haemophilic joint disease.


Sujet(s)
Dependovirus , Facteur VIII , Vecteurs génétiques , Hémophilie A , Matrix Metalloproteinase 13 , Matrix metalloproteinase 3 , ARN long non codant , Animaux , Hémophilie A/génétique , Hémophilie A/thérapie , Hémophilie A/complications , Dependovirus/génétique , ARN long non codant/génétique , Matrix Metalloproteinase 13/métabolisme , Matrix Metalloproteinase 13/génétique , Souris , Matrix metalloproteinase 3/génétique , Matrix metalloproteinase 3/métabolisme , Vecteurs génétiques/génétique , Vecteurs génétiques/administration et posologie , Facteur VIII/génétique , Facteur VIII/métabolisme , Maladies articulaires/thérapie , Maladies articulaires/génétique , Maladies articulaires/étiologie , Humains , Thérapie génétique/méthodes , Souris de lignée C57BL , Cartilage articulaire/métabolisme , Cartilage articulaire/anatomopathologie , Modèles animaux de maladie humaine , Mâle
12.
J Med Genet ; 61(8): 769-776, 2024 Jul 19.
Article de Anglais | MEDLINE | ID: mdl-38719348

RÉSUMÉ

BACKGROUND: Exploring the expression of X linked disorders like haemophilia A (HA) in females involves understanding the balance achieved through X chromosome inactivation (XCI). Skewed XCI (SXCI) may be involved in symptomatic HA carriers. We aimed to develop an approach for dissecting the specific cause of SXCI and verify its value in HA. METHODS: A family involving three females (two symptomatic with severe/moderate HA: I.2, the mother, and II.1, the daughter; one asymptomatic: II.2) and two related affected males (I.1, the father and I.3, the maternal uncle) was studied. The genetic analysis included F8 mutational screening, multiplex ligation-dependent probe amplification, SNP microarray, whole exome sequencing (WES) and Sanger sequencing. XCI patterns were assessed in ectoderm/endoderm and mesoderm-derived tissues using AR-based and RP2-based systems. RESULTS: The comprehensive family analysis identifies I.2 female patient as a heterozygous carrier of F8:p.(Ser1414Ter) excluding copy number variations. A consistent XCI pattern of 99.5% across various tissues was observed. A comprehensive filtering algorithm for WES data was designed, developed and applied to I.2. A Gly58Arg missense variant in VMA21 was revealed as the cause for SXCI.Each step of the variant filtering system takes advantage of publicly available genomic databases, non-SXCI controls and case-specific molecular data, and aligns with established concepts in the theoretical background of SXCI. CONCLUSION: This study acts as a proof of concept for our genomic filtering algorithm's clinical utility in analysing X linked disorders. Our findings clarify the molecular aspects of SXCI and improve genetic diagnostics and counselling for families with X linked diseases like HA.


Sujet(s)
Hémophilie A , Pedigree , Inactivation du chromosome X , Humains , Inactivation du chromosome X/génétique , Femelle , Hémophilie A/génétique , Mâle , Algorithmes , /méthodes , Facteur VIII/génétique , Chromosomes X humains/génétique , Génomique/méthodes , Variations de nombre de copies de segment d'ADN/génétique , Mutation/génétique , Adulte
13.
Bull Hosp Jt Dis (2013) ; 82(2): 124-133, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38739660

RÉSUMÉ

Postoperative venous thromboembolism (VTE) is a common and costly complication following total joint arthroplasty (TJA). Development of a refined thrombophilic screening panel will better equip clinicians to identify patients at high-est risk for developing VTEs. In this pilot study, 62 high-risk TJA recipients who had developed pulmonary emboli (PE) within 90-days of surgery were eligible to participate. Of these patients, 14 were enrolled and subsequently adminis-tered a pre-determined panel of 18 hematologic tests with the aim of identifying markers that are consistently elevated or deficient in patients developing PE. A separate cohort of seven high-risk TJA recipients who did not report a symp-tomatic VTE within 90-days of surgery were then enrolled and Factor VIII and lipoprotein(a) levels were assessed. The most common aberrance was noted in 10 patients (71.4%) who had elevated levels of Factor VIII followed by five patients (35.7%) who had elevated levels of lipoprotein(a). Factor VIII was significantly prevalent (p < 0.001) while lipoprotein(a) failed to achieve statistical significance (p = 0.0708). Of the patients who were within normal limits of Factor VIII, three-fourths were "high-normal" with Fac-tor VIII levels within 5% of the upper limit of normal. This study demonstrates the potential utility of this hematologic panel as part of a perioperative screening protocol aimed at identifying patients at risk for developing VTEs. However, future larger scale studies assessing the capabilities and limitations of our findings are warranted.


Sujet(s)
Embolie pulmonaire , Humains , Projets pilotes , Embolie pulmonaire/sang , Embolie pulmonaire/étiologie , Embolie pulmonaire/diagnostic , Femelle , Mâle , Adulte d'âge moyen , Sujet âgé , Facteurs de risque , Appréciation des risques/méthodes , Valeur prédictive des tests , Complications postopératoires/étiologie , Complications postopératoires/diagnostic , Complications postopératoires/sang , Facteur VIII/analyse , Marqueurs biologiques/sang , Lipoprotéine (a)/sang , Arthroplastie prothétique/effets indésirables , Thromboembolisme veineux/étiologie , Thromboembolisme veineux/diagnostic , Thromboembolisme veineux/sang , Thromboembolisme veineux/épidémiologie
14.
Adv Emerg Nurs J ; 46(2): 101-107, 2024.
Article de Anglais | MEDLINE | ID: mdl-38736094

RÉSUMÉ

Patients who develop an intracerebral hemorrhage (ICH) following thrombolysis in acute ischemic stroke (AIS) have a mortality rate as high as 50%. Treatment options include blood products, such as cryoprecipitate, or antifibrinolytics, such as tranexamic acid (TXA) or ε-aminocaproic acid (EACA). Current guidelines recommend cryoprecipitate first-line despite limited data to support one agent over another. In addition, compared to antifibrinolytics, cryoprecipitate is higher in cost and requires thawing before use. This case series seeks to characterize the management of thrombolytic reversal at a single institution as well as provide additional evidence for antifibrinolytics in this setting. Patients were included for a retrospective review if they met the following criteria: presented between January 2011-January 2017, were >18 years of age, were admitted for AIS, received a thrombolytic, and received TXA EACA, or cryoprecipitate. Twelve patients met the inclusion criteria. Ten (83.3%) developed an ICH, one (8.3%) experienced gastrointestinal bleeding, and one (8.3%) had bleeding at the site of knee arthroscopy. Eleven patients received cryoprecipitate (median dose: 10 units), three received TXA (median dose: 1,000 mg), and one patient received EACA (13 g). TXA was administered faster than the first blood product at a mean time of 19 min and 137 min, respectively. Hemorrhagic expansion (N = 8, 66.67%) and inhospital mortality (N = 7, 58.3%) were high. While limited by its small sample size, this case series demonstrates significant variability in reversal strategies for thrombolysis-associated bleeding. It also provides additional evidence for the role of antifibrinolytics in this setting.


Sujet(s)
Antifibrinolytiques , Fibrinogène , Accident vasculaire cérébral ischémique , Acide tranéxamique , Humains , Antifibrinolytiques/usage thérapeutique , Antifibrinolytiques/administration et posologie , Études rétrospectives , Mâle , Femelle , Accident vasculaire cérébral ischémique/traitement médicamenteux , Fibrinogène/usage thérapeutique , Sujet âgé , Acide tranéxamique/usage thérapeutique , Acide tranéxamique/administration et posologie , Traitement thrombolytique , Adulte d'âge moyen , Facteur VIII/usage thérapeutique , Acide 6-amino-caproïque/usage thérapeutique , Sujet âgé de 80 ans ou plus , Hémorragie cérébrale/traitement médicamenteux
15.
Surg Infect (Larchmt) ; 25(4): 291-299, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38700750

RÉSUMÉ

Background: Packed red blood cell (PRBC) transfusion has been shown to increase nosocomial infection risk in the injured population; however, the post-traumatic infectious risk profiles of non-PRBC blood products are less clear. We hypothesized that plasma (fresh frozen plasma [FFP]), platelet (PLT), and cryoprecipitate administration would not be associated with increased rates of nosocomial infections. Patients and Methods: We performed a retrospective, matched, case-control study utilizing the American College of Surgeons National Trauma Data Bank data for 2019. We included all patients who received any volume of PRBC within four hours of presentation. Our outcome of interest was any infection. Controls were matched to cases using individual matching with a desired 1:3 case:control ratio. Bivariable analysis according to infection status, and multivariable logistic regression modeling the development of infection were then performed upon the matched data. Results: A total of 1,563 infectious cases were matched to 3,920 non-infectious controls. First four-hour transfusion volumes for FFP, PLT, and cryoprecipitate in the infection group exceeded those in the control group. The first four-hour FFP transfusion volume (per unit odds ratio [OR], 1.02; 95% confidence interval [CI], 0.99-1.04; p = 0.28) and cryoprecipitate transfusion volume (per unit OR, 1.01; 95% CI, 0.99-1.02; p = 0.43) were similar in cases and controls whereas PLT transfusion volume (per unit OR, 0.92; 95% CI, 0.86-0.98; p = 0.01) was lower in cases of infection than in controls. Conclusions: Fresh frozen plasma, PLT, and cryoprecipitate transfusion volumes were not independent risk factors for the development of nosocomial infection in a trauma population. PLT transfusion volume was associated with less infection.


Sujet(s)
Plasma sanguin , Plaies et blessures , Humains , Études rétrospectives , Mâle , Femelle , Adulte , Plaies et blessures/complications , Plaies et blessures/thérapie , Plaies et blessures/épidémiologie , Adulte d'âge moyen , Études cas-témoins , Fibrinogène/analyse , Infection croisée/épidémiologie , Facteur VIII , Transfusion de composants du sang/statistiques et données numériques , Transfusion de composants du sang/effets indésirables , Sujet âgé , Bases de données factuelles , Jeune adulte
17.
Expert Rev Hematol ; 17(6): 233-240, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38708599

RÉSUMÉ

INTRODUCTION: Acquired hemophilia A (AHA) is a rare hemorrhagic autoimmune disorder characterized by autoantibodies against coagulation factor VIII (FVIII). In approximately half of the cases AHA does not recognize any cause (idiopathic form), while in the other cases it may be triggered by autoimmune disorders, cancers, drugs, infections, or pregnancy. Besides treating the underlying disorder, specific AHA treatment includes management of bleeding, if necessary, and inhibitor eradication. AREAS COVERED: This narrative review summarizes the main epidemiological, clinical, laboratory, and therapeutic characteristics of AHA. In particular, it is focused on the current therapeutic options for the inhibitor eradication, also showing the latest findings on the innovative therapies. A literature search strategy was performed, without temporal limits, through Medline and PubMed electronic databases. EXPERT OPINION: Various first-line and second-line immunosuppressive agents are currently available for the management of AHA. Among the latter, the anti-CD20 monoclonal antibody rituximab has been the object of intense research during the last years from investigators as innovative promising eradicating therapy for AHA. Preliminary data from the studies support the use of this drug as a first-line option for newly diagnosed AHA cases.


Sujet(s)
Facteur VIII , Hémophilie A , Immunosuppresseurs , Humains , Hémophilie A/traitement médicamenteux , Hémophilie A/thérapie , Hémophilie A/immunologie , Facteur VIII/usage thérapeutique , Facteur VIII/immunologie , Immunosuppresseurs/usage thérapeutique , Autoanticorps/immunologie , Rituximab/usage thérapeutique , Prise en charge de la maladie
18.
Thromb Res ; 238: 185-196, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38729030

RÉSUMÉ

BACKGROUND: Plaque erosion, a type of coronary atherothrombosis, involves superficial injury to smooth muscle cell (SMC)-rich plaques. Elevated levels of coagulation factor VIII (FVIII) correlate with an increased ischemic heart disease risk. FVIII may contribute to thrombus formation on eroded plaques. AIMS: We aimed to elucidate the role of elevated FVIII in arterial thrombus formation within SMC-rich neointima in rabbits. METHODS AND RESULTS: We assessed the effect of recombinant human FVIII (rFVIII) on blood coagulation in vitro and platelet aggregation ex vivo. An SMC-rich neointima was induced through balloon injury to the unilateral femoral artery. Three weeks after the first balloon injury, superficial erosive injury and thrombus formation were initiated with a second balloon injury of the bilateral femoral arteries 45 min after the administration of rFVIII (100 IU/kg) or saline. The thrombus area and contents were histologically measured 15 min after the second balloon injury. rFVIII administration reduced the activated partial thromboplastin time and augmented botrocetin-induced, but not collagen- or adenosine 5'-diphosphate-induced, platelet aggregation. While rFVIII did not influence platelet-thrombus formation in normal intima, it increased thrombus formation on SMC-rich neointima post-superficial erosive injury. Enhanced immunopositivity for glycoprotein IIb/IIIa and fibrin was observed in rFVIII-administered SMC-rich neointima. Neutrophil count in the arterial thrombus on the SMC-rich neointima correlated positively with thrombus size in the control group, unlike the rFVIII group. CONCLUSIONS: Increased FVIII contributes to thrombus propagation within erosive SMC-rich neointima, highlighting FVIII's potential role in plaque erosion-related atherothrombosis.


Sujet(s)
Facteur VIII , Myocytes du muscle lisse , Néointima , Thrombose , Lapins , Animaux , Néointima/anatomopathologie , Néointima/sang , Thrombose/sang , Thrombose/anatomopathologie , Mâle , Myocytes du muscle lisse/anatomopathologie , Myocytes du muscle lisse/effets des médicaments et des substances chimiques , Tunique intime/anatomopathologie , Tunique intime/effets des médicaments et des substances chimiques , Humains , Agrégation plaquettaire/effets des médicaments et des substances chimiques , Artère fémorale/anatomopathologie , Artère fémorale/traumatismes
19.
Expert Rev Hematol ; 17(7): 341-351, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38752747

RÉSUMÉ

INTRODUCTION: Hereditary thrombotic thrombocytopenic purpura (hTTP) is caused by deficiency of plasma ADAMTS13 activity, resulting from ADAMTS13 mutations. ADAMTS13 cleaves ultra large von Willebrand factor (VWF), thus reducing its multimer sizes. Hereditary deficiency of plasma ADAMTS13 activity leads to the formation of excessive platelet-VWF aggregates in small arterioles and capillaries, resulting in hTTP. AREAS COVERED: PubMed search from 1956 to 2024 using thrombotic thrombocytopenic purpura and therapy identified 3,675 articles. Only the articles relevant to the topic were selected for discussion, which focuses on pathophysiology, clinical presentations, and mechanisms of action of emerging therapeutics for hTTP. Current therapies include infusion of plasma, or coagulation factor VIII, or recombinant ADAMTS13. Emerging therapies include anti-VWF A1 aptamers or nanobody and gene therapies with adeno-associated viral vector or self-inactivated lentiviral vector or a sleeping beauty transposon system for a long-term expression of a functional ADAMTS13 enzyme. EXPERT OPINION: Frequent plasma infusion remains to be the standard of care in most parts of the world, while recombinant ADAMTS13 has become the treatment of choice for hTTP in some of the Western countries. The success of gene therapies in preclinical models may hold a promise for future development of these novel approaches for a cure of hTTP.


Sujet(s)
Protéine ADAMTS13 , Thérapie génétique , Purpura thrombotique thrombocytopénique , Humains , Purpura thrombotique thrombocytopénique/thérapie , Purpura thrombotique thrombocytopénique/génétique , Protéine ADAMTS13/génétique , Protéine ADAMTS13/métabolisme , Protéine ADAMTS13/déficit , Facteur de von Willebrand/métabolisme , Facteur de von Willebrand/génétique , Anticorps à domaine unique/usage thérapeutique , Prise en charge de la maladie , Facteur VIII/génétique , Facteur VIII/usage thérapeutique , Facteur VIII/métabolisme , Mutation , Animaux
20.
Haemophilia ; 30(4): 925-932, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38738967

RÉSUMÉ

INTRODUCTION: Web-Accessible Population-Pharmacokinetic Service-Haemophilia (WAPPS-Hemo) data are available to study factor-concentrate usage, defined as the required weekly dose to achieve a 3% trough (WD3T), across standard and extended half-life (SHL/EHL) products. AIM: To provide baseline usage data including (i) differences across plasma-derived (pdSHL) versus recombinant (rSHL) products, (ii) SHL versus EHL, and (iii) effect of age and positive inhibitor history. METHODS: PK profiles (n = 14,416 patients, 0.3-85.2 years) and linear mixed effects models were used to estimate usage versus age, controlling for significant factors, using 95% confidence intervals to perform comparisons across all ages and posthoc tests to assess the differences. RESULTS: Average usage was significantly higher for pdSHL versus rSHL in patients with a positive inhibitor history (PIH; 1.9-2.5 times higher), for SHL versus EHL (4-10 times), and was significantly associated with age. CONCLUSION: Baseline usage patterns from 2017 to early 2023 provide a benchmark for assessing the impact of emerging technologies in haemophilia.


Sujet(s)
Hémophilie A , Humains , Hémophilie A/traitement médicamenteux , Adulte , Adolescent , Jeune adulte , Adulte d'âge moyen , Enfant , Sujet âgé , Enfant d'âge préscolaire , Mâle , Nourrisson , Sujet âgé de 80 ans ou plus , Facteurs âges , Femelle , Facteur VIII/usage thérapeutique , Facteur VIII/pharmacocinétique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE